Claims for Patent: 11,707,454

Summary for Patent: 11,707,454

Title:	Topical roflumilast formulation having antifungal properties
Abstract:	The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
Inventor(s):	David Reuben BERK, Patrick Eugene BURNETT, Saori Kato, David W. Osborne
Assignee:	Arcutis Biotherapeutics Inc
Application Number:	US17/542,072
Patent Claims:	1. A method of treating a fungal infection in a subject in need thereof, comprising administering to the subject a composition comprising an antifungal effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection is caused by Malassezia spp. 2. The method according to claim 1, wherein said roflumilast is administered topically. 3. The method according to claim 1, wherein said Malassezia spp. is selected from the group consisting of M. furfur, M. restricta, and M. globosa. 4. The method according to claim 3, wherein said Malassezia spp. is M. furfur. 5. The method according to claim 1, wherein the fungal infection comprises fungal overgrowth of hair, skin or nails. 6. The method according to claim 1, wherein said subject is suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, or Tinea incognito. 7. The method according to claim 6, wherein said subject is suffering from seborrheic dermatitis. 8. The method according to claim 1, wherein said composition comprises carriers suitable for topical administration. 9. The method according to claim 1, wherein said composition is selected from the group consisting of an aerosol, a foam, a spray, an emulsion, a gel, a liquid, an ointment, a paste, a shampoo, a suspension, and a system. 10. The method according to claim 9, wherein said composition is a foam. 11. The method according to claim 1, wherein said composition comprises 0.3% w/w roflumilast. 12. The method according to claim 1, wherein said composition comprises roflumilast, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben and water. 13. The method according to claim 1, wherein said composition consists of: roflumilast 0.3% w/w white petrolatum 10.0% w/w isopropyl palmitate 5.0% w/w cetearyl alcohol, 10.0% w/w dicetyl phosphate and ceteth-10 phosphate blend hexylene glycol 2.0% w/w diethylene glycol 25.0% w/w monoethyl ether methylparaben 0.2% w/w propylparaben 0.05% w/w, and purified water q.s. ad 100 (47.45%). 14. The method according to claim 1, further comprising administering an additional anti-fungal agent and/or an anti-inflammatory agent. 15. The method according to claim 14 wherein said additional anti-fungal agent is selected from the group consisting of: drugs containing miconazole, ciclopirox olamine, clotrimazole, butenafine, terbinafine, amorolfine, naftifine, tolnaftate, ketoconazole, efinaconazole, griseofulvin, imidazoles, triazole, voriconazole, benzimidazole, ethylparaben, flucytosine, salicylic acid, selenium sulfide, and undecylenic acid. 16. The method according to claim 14 wherein said additional anti-inflammatory agent is a corticosteroid or a calcineurin inhibitor. 17. A method of treating a fungal infection, fungal overgrowth and/or hypersensitivity to Malassezia spp in a subject in need thereof, comprising topically administering to the subject an antifungal effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection or overgrowth is caused by Malassezia spp.